

Public Interest Incorporated Foundation
The NOVARTIS Foundation (Japan) for the Promotion of Science
Business Report & Financial Statements

Fiscal 2023 (37th fiscal year) (April 1, 2023 - March 31, 2024)

The Foundation was established on September 4, 1987 with the approval of the Minister of Education and Culture and was converted to a public interest foundation on April 1, 2012 with the approval of the Cabinet Office. Since its establishment, the Foundation has been providing public service to the public, and the current status of its operations, general affairs and accounts for fiscal year 2023 (the 36th fiscal year) are as follows

I. Business Situations

1. The 37th Novartis Research Grant

The purpose of the grant is to support creative research conducted in Japan in the fields of biological and life sciences and related chemistry and information science. We requested nominations of candidates from 617 persons, including the heads of national, public and private universities, research institutes and affiliated hospitals, as well as trustees and councilors of the Foundation, and received 247 nominations. The Selection Committee selected 41 candidates (plus two runners-up), and the Board of Trustees made the decision. A total of 41 million yen was awarded in April 2024, with each award amounting to 1 million yen. The ratio of adoption was 6.0 times.

2. Research Meeting Grant

The purpose of the grant is to support research meetings of international interest held in Japan in the fields of biological and life sciences and related chemistry and information science.

FY2023 Meeting: Five candidates (one runner-up) were selected by the Selection Committee from 13 applications, and the decision was made by the Board of Trustees (adoption ratio: 2.6 times). The recipients received 400,000 yen each, for a total of 2 million yen, in April 2024.

3. Annual Report Publication

We have prepared an annual report to expand our understanding of and support for foundation activities. The book of annual reports were distributed to the recipients of the FY 2021 grant and were also posted on the website. The annual reports include the report on the achievements of the 35 (2021) grants recipients, the report on the 2021 research meetings, and the status of the foundation's activities.

II. General Affairs Overview

1. Trustees, Auditors, Councilors and Selection Committee members

The list of Trustees, Auditors, Councilors and Selection Committee members as of July 1, 2023 is on a separate page.

2. Meetings of the Foundation (Board Meeting of Trustees, Board Meeting of Councilors and Grant Selection Committee)

1) 33th Board of Trustees Meeting (May 23, 2023) at Tokyo Kaikan Main Bldg “Azalea”

Number of Trustees 5 (Quorum: 3): Attendees: 4 Directors, 1 Auditors

Proposal 1: Business Report and Settlement of Accounts for FY2023 (Approval of the original proposal)

Proposal 2: Resignation and appointment of selection committee members for FY2023 (Resolved and approved 6 resignations, 6 replacements, and 8 reappointments)

Proposal 3: Confirm the application guidelines for Novartis Research Grant and Research Meetings for FY2023

Proposal 4: Convening of the 16th Meeting of the Board of Councilors (Approval of the original proposal)

1) Matters to be reported: Report on the execution of duties by the Representative Trustee, and status report on the results and achievements of the Research Grants and Research Meetings

2) 16th Meeting of the Board of Councilors (June 16, 2023) at Daiichi Hotel Tokyo “Flora”

Number of Councilors: 10 (Quorum: 6): 8 Councilors in attendance

Proposal 1: Business Report and Settlement of Accounts for FY2023 (Approval of the original proposal)

Proposal 2: Election of Signatories to the Minutes (Approval of the original proposal)

Report: Business Plan and Budget for FY2023 • Retirement and election of selection committee members; • The Application Guidelines for the 37th Novartis Research Grants and Research Meeting, Results of the 33st-35th Novartis Research Grants, Results of on-site inspection by the Cabinet Office

3) Twelfth Selection Committee Meeting (December 18, 2023) at Daiichi Hotel Tokyo “Iris”

Number of Selection Committee members: 20 (Quorum: 11): 13 members in attendance

Agenda 1: Selection of the 37th Novartis Research Grants for FY2023 (38 grants and 3 alternates were selected)

Agenda 2: Selection of Research Meeting Grants for FY 2023 (5 grants and 1 runner-up selected)

4) 34th Board of Trustees Meeting (February 19, 2024) at Tokyo Kaikan Main Building “Iris”

Number of Trustees 5 (Quorum: 3): Attendees: 3 Trustees, 2 Auditors

Proposal 1: Determination of recipients of the 37th Novartis Research Grants and Meeting Grants for FY2023 (Approval of the original proposal)

Proposal 2: Business plan and budget for FY2024 (Approval of original proposal)

Proposal 3: Renewal of the designated institutions of the Novartis Research Grants for FY2024 (Approval of the original proposal)

Proposal 4: Election Policy for Selection Committee Members for FY2024

Proposal 5: Changes to the Rules and Regulations for Grants

Report: Report on the status of execution of duties by Representative Trustee.

3. Matters related to donations

The Foundation received a general donation of 40 million yen from Novartis Pharma K.K., for a total of 40 million yen.

III. Financial statement (FY 2023)

Ordinary income includes 21.04 million yen and 0.68 million yen from the management of basic assets and other assets, respectively, and 40 million yen from donations, for a total ordinary income of 61.72 million yen.

The total ordinary expenses were 53.22 million yen in operating expenses and 4.34 million yen in administrative expenses, for a total ordinary expense of 57.56 million yen.

Operating expenses accounted for 92.4% of recurring expenses, and subsidies of 43 million yen accounted for 80.7% of operating expenses.

The operating expenses were in the black by 1.13 million yen.

Total net assets for the period totaled 1,169.03 million yen, an increase of 4.15 million yen from the previous period.

The Foundation did not raise funds (borrowing) or make any capital investments in fiscal 2023.